A Study of LY3463251 in Healthy Participants: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of LY3463251 in Healthy Participants (NCT03764774), a randomized phase 1 study. The primary outcome is Number of Participants With One or More Adverse Event(s) (AEs), All Causalities.

2. Clinical Question

The study asked whether single and repeated subcutaneous doses of LY3463251 could be evaluated for safety, tolerability, and pharmacokinetics in healthy participants. Its two-part design separated single-dose assessment from repeated-dose assessment: participants enrolled in only one part. The primary outcome counted participants with one or more adverse events, regardless of causality. This is a measure of how many participants experienced an event during follow-up, not a count of every event or a measure of event severity.

The registry also lists pharmacokinetic outcomes for both parts, a Part B glucose outcome, and change in body weight at Day 85 in Part B. These outcomes address drug concentration, a pharmacodynamic measure, and body weight; they do not replace the primary safety-and-tolerability question. Numerical results for most of those listed outcomes are not reported in the registry record.

3. Trial Design

This was a randomized, double-blind, parallel-group Phase 1 study with placebo control. The registry reports an enrollment of 118. It gives the study status as terminated, with a start date of 2018-12-06 and a primary completion date of 2020-12-07. The reason for termination is not reported in the registry record.

The study had two parts, and participants enrolled in only one. Part A assessed single subcutaneous doses of LY3463251, with eight listed dose cohorts spanning 0.01 mg to 24 mg, and a single-dose placebo group. Part B assessed repeated subcutaneous dosing. Its listed active groups included weekly fixed-dose schedules and schedules that increased over time; the multiple-dose placebo group received weekly placebo for 12 weeks. The registry describes Part A as lasting about 10 weeks and Part B as lasting about 23 weeks, including screening.

Double blinding means the study was recorded as masking both participants and investigators, while randomization indicates that assignment was planned to involve chance. The registry record does not describe the randomization procedure, allocation ratios, concealment details, or whether blinding was maintained throughout. It also does not state why the number of participants differs across the posted groups, so those differences should not be interpreted as evidence about the design rationale.

The primary endpoint followed participants from baseline through follow-up, up to Day 42 for Part A and up to Day 123 for Part B. The outcome population is stated as all enrolled participants, including those who did not complete all protocol requirements. This definition is distinct from the number at risk shown for each posted outcome group. A detailed protocol, the trial's own sample-size assumptions, and the reason for termination are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Only the first 6 of 14 groups are shown.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All enrolled participants, whether or not they completed all protocol requirements.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All enrolled participants, whether or not they completed all protocol requirements.

Only the first 6 of 15 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With One or More Adverse Event(s) (AEs), All Causalities, measured over Baseline through follow up in Part A (up to Day 42); Baseline through follow up in Part B (up to Day 123).

The primary endpoint is the number of participants with one or more adverse events, with all causalities included. The registry describes the endpoint as a count of participants, not a count of all events. A participant with several events therefore contributes to this measure as a participant who experienced at least one event; the endpoint does not convey how many events that person had.

This outcome is used in a safety-and-tolerability study because it records whether participants experienced adverse events over the specified follow-up. The phrase “all causalities” means the measure is not restricted to events judged related to LY3463251. That broad definition can capture events occurring during participation without attributing them to the study drug. It also means the count alone cannot establish whether an event was caused by treatment.

The record separately identifies serious adverse events and other non-serious adverse events in its adverse-event reporting. Those categories add information about seriousness, while the primary endpoint combines adverse events regardless of causality. The primary endpoint is not a measure of pharmacokinetic exposure, glucose response, or body-weight change. Those are listed separately among the secondary outcomes.

Follow-up differs by part: baseline through follow-up in Part A, up to Day 42, and baseline through follow-up in Part B, up to Day 123. Comparisons across the two parts therefore should not be treated as if they came from a single common follow-up window. The count is also imprecise when groups are small: a few participants can substantially influence the observed count, and a count does not by itself describe the range of possible underlying event rates.

7. Results Posted in the Registry

• Placebo Multiple Dose: 38.5% (5/13) versus 6.2% (1/16) on control; risk difference 32.2 percentage points (95% CI 3.2 to 61.2), risk ratio 6.15 (0.82–46.32); unadjusted two-proportion z-test p = 0.033.
• 1 mg LY3463251 Part B Cohort 1: 50.0% (5/10) versus 6.2% (1/16) on control; risk difference 43.8 percentage points (95% CI 10.6 to 76.9), risk ratio 8.00 (1.09–58.90); unadjusted two-proportion z-test p = 0.010.
• 3 mg LY3465231 Part B Cohort 2: 50.0% (5/10) versus 6.2% (1/16) on control; risk difference 43.8 percentage points (95% CI 10.6 to 76.9), risk ratio 8.00 (1.09–58.90); unadjusted two-proportion z-test p = 0.010.
• 3/6/9 mg LY3463251 Part B Cohort 3: 72.2% (13/18) versus 6.2% (1/16) on control; risk difference 66.0 percentage points (95% CI 42.1 to 89.8), risk ratio 11.56 (1.70–78.76); unadjusted two-proportion z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Change From Baseline in Body Weight at Day 85 Part B

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • 1 mg LY3463251 QW: mean 0.77 versus 2.11 on control; difference -1.34 (95% CI -3.26 to 0.58), standardized effect d = -0.61; z-test p = 0.171.
  • 3/6/9 mg LY3463251 QW: mean -0.28 versus 2.11 on control; difference -2.39 (95% CI -3.76 to -1.02), standardized effect d = -1.21; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between 1 mg LY3463251 QW and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for 3/6/9 mg LY3463251 QW than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The registry lists pharmacokinetic outcomes for single- and multiple-dose LY3463251, a Part B glucose outcome, and change from baseline in body weight at Day 85 in Part B. These outcomes address different questions from the primary adverse-event count: drug concentration, a pharmacodynamic measure, and a body-weight measure. The registry record does not report numerical results for most of the listed pharmacokinetic and glucose outcomes, so their pattern cannot be assessed from the posted results.

For the body-weight outcome, posted means are available for placebo, 1 mg weekly, and the 3/6/9 mg weekly schedule. The recalculated comparison with placebo is reported for the 1 mg weekly group and the 3/6/9 mg weekly group. The 1 mg weekly mean difference is -1.34, with a confidence interval from -3.257 to 0.577 and an unadjusted p-value of 0.171. The 3/6/9 mg weekly mean difference is -2.39, with a confidence interval from -3.765 to -1.015 and an unadjusted p-value of <0.001. These are separate outcomes from the primary count and should not be interpreted as evidence about adverse events.

The overall secondary-outcome record is incomplete: several outcomes are named without numerical results, and the registry lists no reported analyses. The available weight comparisons are recalculations from posted summary values, rather than a substitute for a prespecified trial analysis. Their uncertainty and the small group sizes matter when interpreting the estimates.

Secondary outcomes generally carry less weight than the primary outcome for a confirmatory conclusion, particularly when the analysis plan and multiplicity strategy are not reported. Examining many outcomes and dose comparisons increases the chance that some results appear notable by chance. The registry does not report an adjustment for multiple comparisons. The secondary findings are best treated as descriptive context that may inform further study, while keeping the primary safety outcome, the outcome definitions, and the limits of the record distinct.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3463251 Part A
• PK: Maximum Observed Concentration of LY3463251 Part B
• PK: Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tlast]) of LY3463251 Part A
• PK: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUC[0-tau)] for LY3463251 Part B
• Pharmacodynamics (PD): AUC (0-2hours) of Glucose Part B
• Change From Baseline in Body Weight at Day 85 Part B

9. Statistical Interpretation

10. Statistical Methods Explained

The posted comparisons are unadjusted recalculations from the group counts. They are useful for describing how the observed proportions differ, but they are not a substitute for a prespecified analysis from the trial. The registry lists no reported analyses. The calculations therefore should be understood as descriptive statistical comparisons of posted summary data.

What does a risk difference express?

A risk difference compares the proportion of participants with an event in one group with the corresponding proportion in another group. A positive estimate in these comparisons indicates a larger observed proportion in the LY3463251 group than in the multiple-dose placebo group. It is an absolute comparison, rather than a relative measure. For example, the Part B comparison for 3/6/9 mg has an estimated risk difference of 0.660. The confidence interval, from 0.421 to 0.898, describes uncertainty around that estimate under the method used for the recalculation.

Risk differences are often straightforward to interpret because they express the scale of the group contrast directly. Their precision depends on the data, including how many participants were observed and how many had the outcome. With small groups, individual outcomes can have a large influence on the estimate. The Part B cohorts are not all the same size, and several contain relatively few participants, so their estimates should be read with the corresponding intervals and group counts in mind.

How should a confidence interval be read?

A confidence interval gives a range of values compatible with the observed data under the statistical procedure used. It is not a guarantee that the true value lies in that particular interval, nor does it express the probability that a treatment caused an event. Wider intervals indicate less precision. Intervals that include values close to no difference and values indicating a larger difference leave more uncertainty about the magnitude. Statistical significance and clinical importance are separate questions; the registry does not establish a threshold for judging the importance of these event-count contrasts.

What does an unadjusted p-value tell the reader?

An unadjusted p-value describes how inconsistent the observed data are with a specified no-difference model, under the assumptions of the test. It does not give the probability that the no-difference model is true, and it does not measure the size or importance of an effect. The reported p-values are labelled unadjusted. Because the registry does not report whether or how multiple comparisons were addressed, these values should not be treated as accounting for the number of dose groups or endpoints examined.

The comparison results also include relative measures in the calculated output, but the risk-difference scale is used in the interpretation because it directly describes the absolute contrast in observed event proportions. Relative measures can look large when the comparison group has few events, and their intervals can be broad. No measure, by itself, resolves the limitations created by small groups, the broad all-causality endpoint, or the absence of a reported analysis plan.

Why are the outcome counts not the same as an event rate over time?

The primary endpoint counts participants who had at least one event during follow-up. It does not incorporate the precise timing of events or the length of each participant's observed time as a rate calculation would. The follow-up windows are stated separately for Part A and Part B, and participants may not all have completed every protocol requirement. The endpoint population includes all enrolled participants, while the posted group counts identify participants at risk for that outcome. The registry does not report additional details needed to reconstruct individual follow-up or conduct a time-to-event analysis.

What limits do the recalculations have?

The calculations use the posted summary counts and do not adjust for baseline characteristics, study part, dose schedule, or other variables. They also do not reproduce a sponsor analysis, because no reported analyses are listed in the record. The recalculated p-values and intervals should therefore be treated as exploratory descriptions of the posted group data, rather than as confirmatory findings. The trial's own statistical methods, including any planned model, missing-data procedures, interim analyses, or multiplicity adjustment, are not reported in the registry record.

11. Confidence Intervals and Precision

Precision is best assessed by reading each estimate alongside its confidence interval and the corresponding group sizes. The interval for the Part B placebo comparison runs from 0.032 to 0.612 around a risk-difference estimate of 0.322. The interval for each of the 1 mg weekly and 3 mg weekly comparisons runs from 0.106 to 0.769 around an estimate of 0.438. For the 3/6/9 mg schedule, the interval runs from 0.421 to 0.898 around an estimate of 0.660.

These intervals are broad, leaving uncertainty about the magnitude of each difference. The estimates come from small groups: the comparator has 13 participants, while the active groups in these comparisons have 10, 10, and 18 participants. As a general statistical point, small samples tend to produce less precise estimates, especially for outcomes that are counts of participants with an event. This matters even when an unadjusted p-value is small: a small p-value does not make the estimated size precise or remove uncertainty about its relevance.

The confidence intervals are for unadjusted recalculated comparisons. They do not account for any multiplicity adjustment or covariate adjustment, because such procedures are not reported. The single-dose groups are also small, with 6 participants in each active cohort. Their raw counts describe what was observed in those cohorts, but the record does not provide corresponding comparative confidence intervals for those single-dose groups.

Intervals should not be interpreted as evidence about causality. The endpoint includes events regardless of causality, and the available group summaries do not show individual event histories. The registry record also does not report a prespecified threshold for a meaningful difference. Thus, the statistical precision of the estimates and their practical or clinical meaning remain distinct considerations.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size display is a planning illustration based on the observed effect in each comparison, not a report of the trial's original design assumptions. Its entries are participants per arm for both the 80% power and 90% power columns. The stated planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The target effect is the stated fraction of the observed effect. The original sample-size justification is not reported in the registry record.

In plain language, the 80% power column gives the estimated participants per arm for a future study to have an 80% chance of detecting the chosen effect under those assumptions, if that effect is real. The 90% power column gives the corresponding planning count for a higher chance of detection. These are design calculations, not descriptions of the number enrolled or the chance that the current trial found a real effect. This is not observed power.

The display scales the target effect to 100%, 75%, or 50% of the observed effect. Smaller effects are harder to distinguish from random variation, so they require more participants. For example, for the 3/6/9 mg primary-outcome comparison, planning at 100% of the observed effect gives 8 participants per arm for 80% power and 10 for 90% power; planning at 50% gives 25 and 32, respectively. These values are illustrations dependent on the assumptions above, not recommendations or guarantees.

For the primary binary outcome, the entries refer to participants per arm, not total events. The display also includes a body-weight comparison, for which the same per-arm interpretation applies. The event-count convention for time-to-event outcomes is not relevant to these comparisons. The curve should be read as a visual presentation of the same planning relationship: as the effect selected for detection becomes smaller, the participant requirement rises. It does not show the number actually observed in the trial.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.062; treatment proportion p₁ = 0.385; average p̄ = 0.224.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.5892 = 1.1548.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.5434 = 0.4573.
4. n = (1.1548 + 0.4573)² / (0.3221)² = 25.0, rounded up to 26 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.0625                          # control proportion
p1 <- 0.384615384615385                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(3764774)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 26 (80% power), 34 (90% power)
 75% of observed effect: n per arm = 40 (80% power), 52 (90% power)
 50% of observed effect: n per arm = 73 (80% power), 98 (90% power)
power.prop.test: 25 
Simulated power at n = 26 per arm: 0.861 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry record does not report a statistical analysis plan describing how the primary outcome was to be analyzed. It does not report a plan for handling multiple comparisons across dose groups, the two study parts, or the listed outcomes. The calculated comparisons are labelled unadjusted, and the reported analyses list is empty. Consequently, the p-values should not be interpreted as if they incorporate a family-wise or other multiplicity adjustment.

Multiplicity matters because testing several groups or outcomes creates more opportunities for apparently unusual results to occur by chance. A correction or a clearly defined hierarchy can address that issue, but the record does not state whether the trial used either approach. It is therefore not possible to infer the intended confirmatory status of individual comparisons or identify which comparisons, if any, were prespecified.

The primary endpoint population is defined as all enrolled participants, whether or not they completed all protocol requirements. However, the registry does not explain how missing outcome information was handled, how incomplete follow-up was treated, or whether any imputation or sensitivity analyses were performed. The number at risk shown for each posted group does not, by itself, explain whether every enrolled participant contributed complete outcome data or why any participant might be absent from a group summary.

The record also does not report interim analyses, stopping rules, covariate adjustment, or methods for handling protocol deviations. The trial's original sample-size justification and assumptions are not reported in the registry record; the planning illustrations are based on observed effects and are not the original design calculation. The reason for termination is also not reported. These omissions limit assessment of how the observed results relate to the intended design and how robust the statistical conclusions would be under alternative analysis choices.

These are reporting limitations, not evidence that a particular method was or was not used. The registry record alone does not establish whether additional methods were described elsewhere or used by the sponsor. Without those details, the safest statistical reading is descriptive and cautious.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The adverse-event record lists zero serious adverse events in every posted group, including the single-dose placebo group, the single-dose LY3463251 cohorts, the multiple-dose placebo group, and the multiple-dose LY3463251 cohorts. It also lists zero deaths in every group. The number at risk varies across groups, so the zero counts should be read together with the group sizes: the serious-event populations range from 3 to 18 in the posted arms.

A group with no observed serious adverse events does not establish that serious events cannot occur. With small groups, the data provide limited information about uncommon events, and a zero count is compatible with uncertainty about the underlying risk. The registry lists no top serious-event terms. The available serious-event figures do not describe the types or timing of non-serious events.

Other non-serious adverse events are recorded separately, while the primary endpoint counts participants with one or more adverse events regardless of causality. Those counts should not be confused with the serious-event totals. The registry's description states that a summary of serious and other non-serious adverse events is reported in the adverse-event module, but the figures alone do not establish whether an event was caused by LY3463251.

16. What the Result Does, and Does Not, Mean

The posted results describe event counts in small, separate dose cohorts and provide selected unadjusted comparisons between Part B LY3463251 groups and multiple-dose placebo. For those comparisons, the calculated risk differences are positive, and their confidence intervals and unadjusted p-values quantify the data under the recalculation method. These statistics do not determine why events occurred. Because the endpoint includes all causalities, an event counted during follow-up is not necessarily attributable to the assigned treatment.

The results also do not establish that LY3463251 is safe or unsafe. Zero serious adverse events and deaths in the posted groups mean none were recorded in those groups, not that the risk is absent. The group sizes are limited, and uncommon outcomes may not appear in a small study. Non-serious adverse-event counts are present, but the endpoint summary does not give event detail or severity for each participant.

This was a Phase 1 study in healthy participants, designed to evaluate safety, tolerability, and pharmacokinetics across single and repeated dosing. It was not a clinical efficacy study in people with a disease condition. The registry lists pharmacokinetic, glucose, and body-weight outcomes, but numerical results for most of these outcomes are not reported in the registry record. The posted weight comparisons are secondary and should not be taken as evidence of a clinical benefit.

The study status is terminated, but the registry does not report the reason. Nor does it report a complete statistical analysis plan, multiplicity handling, or missing-data methods. Those absences constrain how strongly the results can be interpreted. The recalculated estimates are descriptive comparisons from summary data; they are not a replacement for a reported sponsor analysis or a prespecified analysis. Overall, the record offers a limited snapshot of observed events and selected secondary outcomes, with meaningful uncertainty around the estimates and no basis for conclusions beyond the populations, outcomes, and follow-up described.

17. Why This Trial Matters Statistically

This trial is statistically notable because it illustrates how much uncertainty can remain when a study distributes a modest enrollment across multiple dose cohorts and two distinct study parts. The primary outcome is a participant count, but the group sizes differ, and some groups are small. That structure makes it important to read each count in the context of its denominator and not to rank doses simply by their observed counts.

The study also shows why absolute differences, confidence intervals, and raw group counts are complementary. A risk difference gives an absolute contrast, while its interval communicates uncertainty about the magnitude. A p-value alone cannot express that uncertainty or explain whether a difference is meaningful. The calculated intervals are broad, and the estimates arise from unadjusted comparisons; both features deserve attention alongside the observed results.

Multiplicity is especially relevant in a dose-ranging study with several cohorts and multiple outcomes. The registry record does not describe a multiplicity strategy, so unadjusted comparisons should not be treated as definitive evidence that separates dose effects from chance variation. The record's empty reported-analyses list further underscores the difference between an exploratory recalculation and a documented trial analysis.

Finally, the planning illustrations demonstrate that sample-size requirements depend on the effect a future study aims to detect. Planning around a smaller fraction of an observed effect requires more participants under the stated assumptions. Those illustrations are not observed power and do not explain the original design. This distinction is useful when interpreting a small early-phase study: the data can describe observed patterns, but the trial's design rationale and the precision needed for later decisions are not established by the registry record.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The trial's population limits generalization. It enrolled healthy participants and included healthy and overweight healthy subjects in its title; the record does not describe a patient population with a disease condition. Its Phase 1 purpose was safety, tolerability, and pharmacokinetics, so the posted findings do not answer a treatment-efficacy question in patients.

The study's two parts used different dosing schedules and follow-up windows. Part A evaluated single doses with follow-up up to Day 42, while Part B evaluated weekly dosing with follow-up up to Day 123. The primary results therefore do not all arise from the same exposure pattern or observation period. The registry also lists multiple dose cohorts with unequal group sizes, including very small cohorts, which limits precision and makes simple cross-cohort comparisons difficult.

The primary endpoint includes adverse events regardless of causality. It records whether participants had one or more events, but the endpoint does not capture event frequency per participant, timing, or a graded measure of severity. Serious and non-serious events are described separately, yet the registry record does not provide serious-event terms, and the primary counts cannot establish attribution to treatment.

Formal analyses are not reported in the registry record. The analysis plan, multiplicity handling, missing-data procedures, interim analyses, and reason for termination are also not reported. The calculated comparisons are unadjusted, and the planning illustrations rely on observed effects rather than the trial's original design assumptions. Numerical results for most listed pharmacokinetic and glucose outcomes are not reported in the registry record. Taken together, these limitations support a descriptive reading and leave important questions about statistical robustness and the study's conduct unanswered.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: A Study of LY3463251 in Healthy Participants — NCT03764774.
• Registry record last updated 2025-11-04; status last verified 2025-10.
• Results first posted 2025-11-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

NCT03764774 is a randomized, double-blind, placebo-controlled, parallel-group Phase 1 study of LY3463251 in healthy participants. The registry reports enrollment of 118 and a terminated status. The study had a single-dose Part A and a repeated-dose Part B; participants enrolled in only one part.

The primary outcome counted participants with one or more adverse events, regardless of causality. Posted counts vary by cohort, and selected Part B comparisons with multiple-dose placebo have been recalculated as unadjusted risk differences. The registry also lists pharmacokinetic, glucose, and body-weight outcomes, but numerical results for most listed secondary outcomes are not reported in the registry record.

No formal analyses are listed. The original sample-size assumptions, analysis plan, missing-data methods, multiplicity approach, and reason for termination are not reported in the registry record. The results are therefore best read as descriptive observations from a small, early-phase dose-ranging study, with uncertainty around the comparisons and no basis for conclusions about clinical efficacy.